MedTrace Logo

Ilomedin Treatment for Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)

NCT01179776 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2011-06-02

No results posted yet for this study

Summary

Acute myocardial infarct patients with STEMI (ST-elevation on ECG) whom undergo a primary percutaneous cardiac intervention will following the standard treatment , received low dose of Ilomedin and to low dose of standard treatment for another 24 hours.

Conditions

  • Myocardial Infarct

Interventions

DRUG

Ilomedin

Ilomedin

DRUG

Placebo

i.v saline

DRUG

Ilomedin

DRUG

Ilomedin and standard low dose treatment

Sponsors & Collaborators

  • Lene Holmvang

    collaborator UNKNOWN

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Thrombologic ApS

    lead INDUSTRY

Principal Investigators

  • Lene Holmvang, MD · Rigshospitalet, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-05-31
Completion
2011-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01179776 on ClinicalTrials.gov